Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionNisa Investment Advisors, Llc
Latest Disclosed Ownership4,947 shares
Latest Disclosed Value $ 146,975
Nisa Investment Advisors, Llc reports 22.69% increase in ownership of TVTX / Travere Therapeutics, Inc.

On April 30, 2026 - Nisa Investment Advisors, Llc filed a 13F-HR form disclosing ownership of 4,947 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $146,975 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 15, 2026 disclosing 4,032 shares of Travere Therapeutics, Inc.. This represents a change in shares of 22.69% during the quarter. The current value of the position is $223,604 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-30 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 4,947 915 22.69 147 -5.19 0.0005
2026-01-15 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 4,032 -124 -2.98 154 55.56 0.0005
2025-10-23 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 4,156 0 0.00 99 62.30 0.0004
2025-07-31 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 4,156 -93 -2.19 62 -19.74 0.0003
2025-04-30 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 4,249 -636 -13.02 76 -10.59 0.0004
2025-01-17 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 4,885 39 0.80 85 26.87 0.0003
2024-10-24 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 4,846 -930 -16.10 68 42.55 0.0004
2024-07-19 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 5,776 41 0.71 47 6.82 0.0003
2024-05-02 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 5,735 85 1.50 44 -12.00 0.0003
2024-01-25 2023-12-31 13F TRAVERE THERAPEUTICS XXX 89422G107 5,650 5,121 968.05 51 1,150.00 0.0004
2023-11-02 2023-09-30 13F TRAVERE THERAPEUTICS XXX 89422G107 529 -3,652 -87.35 5 -93.75 0.0000
2023-08-11 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 4,181 1,657 65.65 64 0.0005
2023-05-02 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 2,524 24 0.96 0 0.0004
2023-02-02 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 2,500 -49 -1.92 0 -100.00 0.0004
2022-11-07 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 2,549 49 1.96 63 3.28 0.0005
2022-08-03 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 2,500 -2,170 -46.47 61 -49.17 0.0005
2022-04-29 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 4,670 -190 -3.91 120 -10.45 0.0008
2022-02-03 2021-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 4,860 1,640 50.93 134 71.79 0.0010
2021-10-18 2021-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 3,220 1,000 45.05 78 143.75 0.0005
2021-08-06 2021-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 2,220 -5,400 -70.87 32 -83.16 0.0002
2021-04-26 2021-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 7,620 0 0.00 190 -8.65 0.0012
2021-01-25 2020-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 7,620 3,250 74.37 208 156.79 0.0013
2020-10-20 2020-09-30 13F RETROPHIN COM 761299106 4,370 2,400 121.83 81 102.50 0.0007
2020-07-27 2020-06-30 13F RETROPHIN COM 761299106 1,970 0 0.00 40 37.93 0.0004
2020-04-17 2020-03-31 13F RETROPHIN COM 761299106 1,970 1,000 103.09 29 107.14 0.0003
2020-01-17 2019-12-31 13F RETROPHIN COM 761299106 970 500 106.38 14 180.00 0.0001
2019-10-17 2019-09-30 13F RETROPHIN COM 761299106 470 200 74.07 5 0.00 0.0000
2019-07-12 2019-06-30 13F RETROPHIN COM 761299106 270 0 0.00 5 -16.67 0.0000
2019-04-17 2019-03-31 13F RETROPHIN COM 761299106 270 0 0.00 6 0.00 0.0001
2019-01-17 2018-12-31 13F RETROPHIN COM 761299106 270 0 0.00 6 -25.00 0.0001
2018-10-16 2018-09-30 13F RETROPHIN COM 761299106 270 -30 -10.00 8 0.00 0.0001
2018-07-18 2018-06-30 13F RETROPHIN COM 761299106 300 0 0.00 8 14.29 0.0001
2018-04-10 2018-03-31 13F RETROPHIN COM 761299106 300 -300 -50.00 7 -46.15 0.0001
2018-01-12 2017-12-31 13F RETROPHIN COM 761299106 600 0 0.00 13 -13.33 0.0001
2017-10-13 2017-09-30 13F RETROPHIN COM 761299106 600 0 0.00 15 25.00 0.0002
2017-07-18 2017-06-30 13F RETROPHIN COM 761299106 600 -3,720 -86.11 12 -85.00 0.0001
2017-04-19 2017-03-31 13F RETROPHIN COM 761299106 4,320 3,720 620.00 80 627.27 0.0010
2017-01-24 2016-12-31 13F RETROPHIN COM 761299106 600 600 11 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.